Author

Rita Lemming

Institution: Fulcrum Therapeutics (United States)

Observed institution: Fulcrum Therapeutics (United States)

OpenAlex ID: A5117859009

Pociredir, a novel oral once-daily fetal hemoglobin inducer: Results from the Phase 1b pioneer study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness

2025 · Sheinei Alan, Johnny Mahlangu, et al. · Blood · 3

Safety and efficacy of pociredir in adults with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness: results from the phase 1b PIONEER study

2026 · Sheinei S Alan, Johnny Mahlangu, et al. · Journal of sickle cell disease.

A Phase 1b, Open-label, Multiple-Dose Study Evaluating Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Pociredir in Patients With Sickle Cell Disease (SCD): Trial Design

2025 · Sheinei Alan, Johnny Mahlangu, et al. · Journal of sickle cell disease.

Works count: 3

Citation count: 3

H-index: 1

I10-index: